Potential 40 million-patient PSA (prostate specific antigen) testing market on horizon for Mediwatch
This article was originally published in Clinica
Executive Summary
With its sights set on a global market of 40 million tests per year, Mediwatch is hoping to launch in the US its rapid point-of-care prostate specific antigen (PSA) test - PSAwatch - during autumn 2007, the UK firm told Clinica.